BTAI
Price
$0.07
Change
-$0.05 (-41.67%)
Updated
Sep 4 closing price
Capitalization
2.31M
69 days until earnings call
Intraday BUY SELL Signals
CNTB
Price
$2.01
Change
+$0.10 (+5.24%)
Updated
Sep 9 closing price
Capitalization
126.58M
5 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BTAI vs CNTB

BTAI vs CNTB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BTAI vs. CNTB commentary
Sep 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BTAI is a Hold and CNTB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2026
Stock price -- (BTAI: $0.07 vs. CNTB: $2.01)
Brand notoriety: BTAI and CNTB are both not notable
BTAI represents the Pharmaceuticals: Generic, while CNTB is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BTAI: 410% vs. CNTB: 137%
Market capitalization -- BTAI: $2.31M vs. CNTB: $126.58M
BTAI [@Pharmaceuticals: Generic] is valued at $2.31M. CNTB’s [@Biotechnology] market capitalization is $126.58M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $132.08B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.02B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BTAI’s FA Score shows that 0 FA rating(s) are green whileCNTB’s FA Score has 0 green FA rating(s).

  • BTAI’s FA Score: 0 green, 5 red.
  • CNTB’s FA Score: 0 green, 5 red.
According to our system of comparison, CNTB is a better buy in the long-term than BTAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BTAI’s TA Score shows that 4 TA indicator(s) are bullish while CNTB’s TA Score has 3 bullish TA indicator(s).

  • BTAI’s TA Score: 4 bullish, 4 bearish.
  • CNTB’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BTAI is a better buy in the short-term than CNTB.

Price Growth

BTAI (@Pharmaceuticals: Generic) experienced а -30.93% price change this week, while CNTB (@Biotechnology) price change was -27.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.71%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +30.41%.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.96%. For the same industry, the average monthly price growth was -1.95%, and the average quarterly price growth was +2729.16%.

Reported Earning Dates

BTAI is expected to report earnings on Nov 18, 2026.

CNTB is expected to report earnings on Sep 15, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.71% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-3.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CNTB($127M) has a higher market cap than BTAI($2.31M). CNTB YTD gains are higher at: -28.723 vs. BTAI (-95.381). BTAI has higher annual earnings (EBITDA): -53.41M vs. CNTB (-69.73M). CNTB has more cash in the bank: 31.5M vs. BTAI (12.8M). CNTB has less debt than BTAI: CNTB (596K) vs BTAI (104M). CNTB has higher revenues than BTAI: CNTB (2.95M) vs BTAI (742K).
BTAICNTBBTAI / CNTB
Capitalization2.31M127M2%
EBITDA-53.41M-69.73M77%
Gain YTD-95.381-28.723332%
P/E RatioN/AN/A-
Revenue742K2.95M25%
Total Cash12.8M31.5M41%
Total Debt104M596K17,450%
FUNDAMENTALS RATINGS
BTAI: Fundamental Ratings
BTAI
OUTLOOK RATING
1..100
61
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
99
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
6

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BTAICNTB
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 28 days ago
81%
Bullish Trend 1 day ago
89%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
BTAI
Daily Signal:
Gain/Loss:
CNTB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BTEKX96.12N/A
N/A
BlackRock Technology Opportunities K
MNDCX19.25N/A
N/A
MFS New Discovery C
BRWRX27.91N/A
N/A
MFS Blended Research Growth Eq R1
BVSIX19.01-0.16
-0.83%
Baywood Socially Responsible Instl
NOIYX18.20-0.17
-0.93%
Natixis Oakmark International Y

BTAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BTAI has been loosely correlated with ORMP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BTAI jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BTAI
1D Price
Change %
BTAI100%
N/A
ORMP - BTAI
44%
Loosely correlated
-4.02%
AXON - BTAI
42%
Loosely correlated
-3.05%
INO - BTAI
39%
Loosely correlated
-7.04%
ARRY - BTAI
37%
Loosely correlated
-4.68%
CRDF - BTAI
35%
Loosely correlated
-4.55%
More

CNTB and

Correlation & Price change

A.I.dvisor indicates that over the last year, CNTB has been loosely correlated with AMRN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CNTB jumps, then AMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CNTB
1D Price
Change %
CNTB100%
+5.24%
AMRN - CNTB
55%
Loosely correlated
+0.98%
INKT - CNTB
31%
Poorly correlated
+3.58%
ENTA - CNTB
30%
Poorly correlated
-1.93%
MCRB - CNTB
27%
Poorly correlated
-5.04%
BTAI - CNTB
26%
Poorly correlated
N/A
More